CH676988A5 - - Google Patents

Download PDF

Info

Publication number
CH676988A5
CH676988A5 CH157/88A CH15788A CH676988A5 CH 676988 A5 CH676988 A5 CH 676988A5 CH 157/88 A CH157/88 A CH 157/88A CH 15788 A CH15788 A CH 15788A CH 676988 A5 CH676988 A5 CH 676988A5
Authority
CH
Switzerland
Prior art keywords
amido
cyclohexyl
boc
norleucyl
hydroxy
Prior art date
Application number
CH157/88A
Other languages
German (de)
English (en)
Inventor
Alexander Dr Hagenbach
Rainer Dr Metternich
Emil Dr Pfenninger
Beat Dr Weidmann
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of CH676988A5 publication Critical patent/CH676988A5/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0227—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the (partial) peptide sequence -Phe-His-NH-(X)2-C(=0)-, e.g. Renin-inhibitors with n = 2 - 6; for n > 6 see C07K5/06 - C07K5/10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
CH157/88A 1987-01-21 1988-01-18 CH676988A5 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3701526 1987-01-21
DE3707339 1987-03-07

Publications (1)

Publication Number Publication Date
CH676988A5 true CH676988A5 (zh) 1991-03-28

Family

ID=25851692

Family Applications (1)

Application Number Title Priority Date Filing Date
CH157/88A CH676988A5 (zh) 1987-01-21 1988-01-18

Country Status (13)

Country Link
JP (1) JPS6419053A (zh)
KR (1) KR880009041A (zh)
AU (1) AU1037588A (zh)
BE (1) BE1002212A5 (zh)
CH (1) CH676988A5 (zh)
DK (1) DK22588A (zh)
FR (1) FR2609716A1 (zh)
GB (1) GB2200115B (zh)
IL (1) IL85136A0 (zh)
IT (1) IT1219811B (zh)
MY (1) MY102311A (zh)
NL (1) NL8800100A (zh)
SE (1) SE8800169L (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002011714A2 (en) * 2000-08-09 2002-02-14 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122000A1 (en) 1981-01-07 2004-06-24 Vertex Pharmaceuticals Incorporated. Inhibitors of aspartyl protease
US6878728B1 (en) 1999-06-11 2005-04-12 Vertex Pharmaceutical Incorporated Inhibitors of aspartyl protease
DE3732971A1 (de) * 1987-09-30 1989-04-20 Hoechst Ag Renin-hemmende dipeptide, verfahren zu deren herstellung, diese enthaltende mittel und ihre verwendung
DE3733296A1 (de) * 1987-10-02 1989-04-20 Merck Patent Gmbh Aminosaeurederivate
EP0329295A1 (en) * 1988-02-01 1989-08-23 The Upjohn Company Renin inhibiting peptides with polar end groups
JP2524814B2 (ja) * 1988-08-25 1996-08-14 キッセイ薬品工業株式会社 α―ヒドロキシ―β―アミノ酸の製造方法
CA2010531A1 (en) * 1989-03-06 1990-09-06 Werner Neidhart Amino acid derivatives
US5185284A (en) * 1989-05-22 1993-02-09 Mitsubishi Denki Kabushiki Kaisha Method of making a semiconductor memory device
US5098924A (en) * 1989-09-15 1992-03-24 E. R. Squibb & Sons, Inc. Diol sulfonamide and sulfinyl renin inhibitors
TW225540B (zh) * 1990-06-28 1994-06-21 Shionogi & Co
DK0558657T3 (da) 1990-11-19 1997-07-07 Monsanto Co Retrovirale proteaseinhibitorer
US5614522A (en) * 1990-11-19 1997-03-25 G.D. Searle & Co. Retroviral protease inhibitors
US5510378A (en) * 1990-11-19 1996-04-23 G.D. Searle & Co. Retroviral protease inhibitors
US5475013A (en) * 1990-11-19 1995-12-12 Monsanto Company Retroviral protease inhibitors
CA2096408C (en) * 1990-11-19 2005-02-08 Gary Anthony Decrescenzo Retroviral protease inhibitors
US5482947A (en) * 1990-11-19 1996-01-09 Talley; John J. Retroviral protease inhibitors
JPH06505963A (ja) * 1990-11-19 1994-07-07 モンサント　カンパニー レトロウイルスプロテアーゼ阻害剤
US5475027A (en) * 1990-11-19 1995-12-12 G.D. Searle & Co. Retroviral protease inhibitors
CA2131182C (en) * 1992-05-20 2005-04-26 John S. Ng Method for making intermediates useful in synthesis of retroviral protease inhibitors
ES2155069T3 (es) * 1992-05-21 2001-05-01 Monsanto Co Inhibidores de proteasas retrovirales.
US6022994A (en) 1992-08-25 2000-02-08 G. D. Searle &. Co. Succinoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US5968942A (en) 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
CA2142998C (en) * 1992-08-25 2008-01-29 Michael L. Vazquez N-(alkanoylamino-2-hydroxypropyl)-sulfonamides useful as retroviral protease inhibitors
US5521219A (en) * 1992-08-25 1996-05-28 G. D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US6743929B1 (en) 1992-08-25 2004-06-01 G. D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US6046190A (en) * 1992-08-25 2000-04-04 G.D. Searle & Co. Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors
US7141609B2 (en) 1992-08-25 2006-11-28 G.D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
KR100336699B1 (ko) 1992-08-25 2002-05-13 윌리암스 로저 에이 레트로바이러스 프로테아제 저해제로서 유용한히드록시에틸아미노 술폰아미드
US5830897A (en) * 1992-08-27 1998-11-03 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
US5783701A (en) * 1992-09-08 1998-07-21 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5578606A (en) * 1992-10-30 1996-11-26 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors
US6156768A (en) * 1992-10-30 2000-12-05 G. D. Searle & Co. Alpha- and beta-amino acid hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors
US5756498A (en) * 1992-10-30 1998-05-26 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors
US6337398B1 (en) 1992-10-30 2002-01-08 G.D. Searle & Co. Succinoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors
AU5589294A (en) * 1992-10-30 1994-05-24 G.D. Searle & Co. Succinoylamino hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors
ES2134924T3 (es) * 1992-10-30 1999-10-16 Searle & Co Acidos sulfonilalcanoilamino-hidroxietilamino-sulfamicos utiles como inhibidores de proteasas retrovirales.
US5514801A (en) 1992-12-29 1996-05-07 Monsanto Company Cyclic sulfone containing retroviral protease inhibitors
US5830888A (en) * 1993-04-16 1998-11-03 Monsanto Company Macrocyclic retroviral protease inhibitors
US5750648A (en) * 1993-08-20 1998-05-12 G.D. Searle & Co. Retroviral protease inhibitors and combinations thereof
US5602119A (en) * 1993-10-29 1997-02-11 Vazquez; Michael L. Succinoylamino hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors
US6133444A (en) * 1993-12-22 2000-10-17 Perseptive Biosystems, Inc. Synthons for the synthesis and deprotection of peptide nucleic acids under mild conditions
AU699483B2 (en) * 1994-03-07 1998-12-03 Vertex Pharmaceuticals Incorporated Sulphonamide derivatives as aspartyl protease inhibitors
DE69520947T2 (de) * 1994-07-07 2002-03-28 Pharmeco Lab Inc Diarinopropanole abgeleitet von aminosäuren
EP1059285A3 (en) * 1994-07-07 2001-10-31 Pharm-Eco Laboratories, Inc. Process for the preparation of 1,3-diamino-2-propanol and 1,3-diamino-2-propanone derivatives
US5475138A (en) * 1994-07-07 1995-12-12 Pharm-Eco Laboratories Incorporated Method preparing amino acid-derived diaminopropanols
JP4014220B2 (ja) 1995-01-20 2007-11-28 ジー．ディー．サール アンド カンパニー ビス−スルホンアミドヒドロキシエチルアミノ レトロ ウイルスプロテアーゼインヒビター
US5831117A (en) 1995-01-20 1998-11-03 G. D. Searle & Co. Method of preparing retroviral protease inhibitor intermediates
US6140505A (en) 1995-03-10 2000-10-31 G. D. Searle & Co. Synthesis of benzo fused heterocyclic sulfonyl chlorides
US5756533A (en) * 1995-03-10 1998-05-26 G.D. Searle & Co. Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US6169085B1 (en) 1995-03-10 2001-01-02 G. D. Searle & Company Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
US5985870A (en) * 1995-03-10 1999-11-16 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
US6861539B1 (en) 1995-03-10 2005-03-01 G. D. Searle & Co. Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
EP1188766A1 (en) 1995-03-10 2002-03-20 G.D. Searle & Co. Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US7339078B2 (en) 1995-03-10 2008-03-04 G.D. Searle Llc Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
ES2190793T3 (es) 1995-03-10 2003-08-16 Searle & Co Inhibidores de proteasas retrovirales de heterociclocarbonil aminoacido hidroxietilamino sulfonamida.
US6667307B2 (en) 1997-12-19 2003-12-23 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
US6407134B1 (en) 1995-03-10 2002-06-18 G. D. Searle & Co. Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US5705500A (en) * 1995-03-10 1998-01-06 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
US5776971A (en) * 1995-03-10 1998-07-07 G.D. Searle & Co. Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US6150556A (en) 1995-03-10 2000-11-21 G. D. Dearle & Co. Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US5691372A (en) * 1995-04-19 1997-11-25 Vertex Pharmaceuticals Incorporated Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
US6004957A (en) * 1995-06-07 1999-12-21 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
US6063963A (en) * 1995-07-05 2000-05-16 Pharm-Eco Laboratories, Inc. Amino acid-derived diaminopropanols
US5753660A (en) * 1995-11-15 1998-05-19 G. D. Searle & Co. Substituted sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
JPH11324710A (ja) 1998-05-20 1999-11-26 Hitachi Ltd ガスタービン発電プラント
BR9912169A (pt) 1998-06-19 2001-04-10 Vertex Pharma Inibidores de sulfonamida de protease de aspartil
AU4862799A (en) 1998-07-08 2000-02-01 G.D. Searle & Co. Retroviral protease inhibitors
JP3888095B2 (ja) 2001-07-26 2007-02-28 株式会社日立製作所 ガスタービン設備
US7251926B2 (en) 2001-07-26 2007-08-07 Hitachi, Ltd. Gas turbine installation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1245217A (en) * 1981-12-10 1988-11-22 Joshua S. Boger Renin inhibitory peptides having phe su13 xx deletion
JPS60163899A (ja) * 1984-02-03 1985-08-26 Sankyo Co Ltd レニン阻害ペプチド類
EP0163237A3 (en) * 1984-05-29 1988-04-27 Merck & Co. Inc. Di- and tri-peptidal renin inhibitors
US4645759A (en) * 1984-06-22 1987-02-24 Abbott Laboratories Renin inhibiting compounds
EP0173481A3 (en) * 1984-08-06 1988-12-21 The Upjohn Company Peptides
US4727060A (en) * 1984-11-13 1988-02-23 Ciba-Geigy Corporation Novel 5-amino-4-hydroxyvaleryl derivatives
EP0184855A3 (en) * 1984-12-14 1989-05-03 Abbott Laboratories Resin inhibiting compounds
KR870005013A (ko) * 1985-11-29 1987-06-04 가와무라 요시부미 레닌-억제 올리고펩티드, 그의 제조방법 및 용도
DE3601248A1 (de) * 1986-01-17 1987-07-23 Hoechst Ag Substituierte 4-amino-3-hydroxybuttersaeure-derivate, verfahren zu deren herstellung, diese enthaltende mittel und ihre verwendung

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002011714A2 (en) * 2000-08-09 2002-02-14 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
WO2002011714A3 (en) * 2000-08-09 2003-08-14 Magnesium Diagnostics Inc Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
US6664420B2 (en) 2000-08-09 2003-12-16 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
US6855826B2 (en) 2000-08-09 2005-02-15 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
US7041829B2 (en) 2000-08-09 2006-05-09 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
US7132537B2 (en) 2000-08-09 2006-11-07 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
US7211667B2 (en) 2000-08-09 2007-05-01 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
US7405311B2 (en) 2000-08-09 2008-07-29 Magnesium Diagnostics, Inc. Antagonist of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
US7619097B2 (en) 2000-08-09 2009-11-17 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
US7795450B2 (en) 2000-08-09 2010-09-14 Magnesium Diagnostics, Inc. Antagonist of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
US7982048B2 (en) 2000-08-09 2011-07-19 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
US8129545B2 (en) 2000-08-09 2012-03-06 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states

Also Published As

Publication number Publication date
DK22588A (da) 1988-07-22
KR880009041A (ko) 1988-09-13
JPS6419053A (en) 1989-01-23
GB8801040D0 (en) 1988-02-17
IL85136A0 (en) 1988-06-30
MY102311A (en) 1992-05-28
FR2609716A1 (fr) 1988-07-22
SE8800169L (sv) 1988-07-22
NL8800100A (nl) 1988-08-16
DK22588D0 (da) 1988-01-19
IT1219811B (it) 1990-05-24
GB2200115B (en) 1990-11-14
AU1037588A (en) 1988-09-01
BE1002212A5 (fr) 1990-10-16
GB2200115A (en) 1988-07-27
SE8800169D0 (sv) 1988-01-20
IT8847556A0 (it) 1988-01-21

Similar Documents

Publication Publication Date Title
CH676988A5 (zh)
DE69912379T2 (de) Antithrombosemittel
RU2012556C1 (ru) Способ получения производных циклоалкилглутарамида или их фармацевтически приемлемых солей
EP0184550B1 (de) 5-Amino-4-hydroxyvalerylamid-Derivate
DE60205465T2 (de) Piperazinderivate als agonisten des melanocortin-rezeptors
EP0505868B1 (de) N-Acyl-alpha-aminosäurederivate
EP0608759B1 (de) Piperazinderivate
EP0412350A2 (de) Renininhibitoren, Verfahren zur Herstellung und ihre Verwendung in Arzneimitteln
EP0445796A2 (de) Essigsäurederivate
EP0417698B1 (de) Aminosäurederivate mit reninhemmenden Eigenschaften, Verfahren zu deren Herstellung, diese enthaltende Mittel und deren Verwendung
DE69735710T2 (de) Neue benzo-1,3-dioxolyl-und benzofuranyl substituierte pyrrolidinederivate als endothelin antagonisten
DD216717A5 (de) Verfahren zur herstellung von benzazocinon- und benzazoninon-derivaten
EP0441192A2 (de) Retroisostere Dipeptide, Verfahren zu ihrer Herstellung und ihre Verwendung als Renininhibitoren in Arzneimitteln
EP0796271B1 (de) Dipeptidische p-amidinobenzylamide mit n-terminalen sulfonyl- bzw. aminosulfonylresten
DE4331135A1 (de) Neue antiviral wirksame valinhaltige Pseudopeptide
KR100300566B1 (ko) 피리미디논유도체와그의제조방법및용도
DE60006542T2 (de) Verbindungen die die tryptase-activität hemmen
DE4331134A1 (de) Neue antiviral wirksame Pseudopeptide
EP0252727A1 (en) Novel amino acid derivatives
DE60201415T2 (de) Bisarylderivate mit fsh rezeptor modulierender aktivität
DE4003575A1 (de) Retroisostere dipeptide, verfahren zur herstellung und ihre verwendung als renininhibitoren in arzneimitteln
EP0437729A2 (de) Neue Peptide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel, insbesondere als Arzneimittel gegen Retroviren
DE3800591A1 (de) Neue peptidderivate, ihre herstellung und verwendung
EP0403828A1 (de) Renininhibitorische Peptide, Verfahren zur ihrer Herstellung und ihre Verwendung in Arzneimitteln
EP0410278B1 (de) Renin-hemmende Aminooligohydroxy-Derivate

Legal Events

Date Code Title Description
PL Patent ceased